# Case Report: Efgartigimod demonstrates significant clinical efficacy in double seropositive myasthenia gravis: a case report of a rare variant and analysis of pathomechanisms

## TL;DR

A 68-year-old woman with a rare form of myasthenia gravis showed significant improvement after treatment with efgartigimod, a promising new therapy for this condition.

## Contribution

This is the first documented case of efgartigimod's efficacy in treating double seropositive myasthenia gravis.

## Key findings

- The patient showed complete resolution of symptoms after efgartigimod treatment.
- Sustained clinical remission was maintained for 6 months post-treatment.
- Efgartigimod may offer a viable treatment option when conventional therapies fail.

## Abstract

Double Seropositive Myasthenia Gravis (DSP-MG), a rare variant of Myasthenia Gravis (MG), is defined by the simultaneous presence of both anti-acetylcholine receptor (AChR) antibodies and anti-muscle-specific tyrosine kinase (MuSK) antibodies in the serum of affected individuals. Currently, no standardized therapeutic protocol exists for DSP-MG due to its scarcity and clinical heterogeneity. Herein, we report a case of a 68-year-old female patient with DSP-MG who showed significant clinical improvement during an acute exacerbation after treatment with the FcRn antagonist efgartigimod, following the failure of conventional therapy. After a cycle of efgartigimod treatment, complete resolution of myasthenic symptoms was observed. During the 6-month follow-up, with sustained clinical remission and attainment of Minimal Manifestation Status (MMS). This case represents the first documented use of efgartigimod in a DSP-MG patient, providing preliminary clinical evidence for its potential efficacy in this rare and poorly understood subtype. Our findings contribute to the limited literature on DSP-MG and suggest that FcRn inhibition may offer a viable treatment option where conventional therapies fail. Efgartigimod may represent a potential therapeutic agent for DSP-MG.